SELECT
Laufzeit: 01.01.2024 - 31.12.2027
imported
Kurzfassung
Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib
In Subjects with Moderately to Severely Active SLE.
Laufzeit: 01.01.2024 - 31.12.2027
Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib
In Subjects with Moderately to Severely Active SLE.
